UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 145

Sortiert nach

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

Annals of oncology, 2015-02, Vol.26 (2), p.368-374

2015

Link zum Volltext

Verfügbarkeit prüfen

262 INVITED From New Targets to New Drugs in Prostate Cancer – Other Targets

European journal of cancer (1990), 2011, Vol.47, p.S61-S61

Chi, K.N

2011

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group

Journal of clinical oncology, 2005-01, Vol.23 (3), p.455-460

2005

Link zum Volltext

Verfügbarkeit prüfen

Letter to the editor regarding ‘Misclassified confounders in the second interim analysis of the MAGNITUDE trial’ by P. Chen, M. Liu, G.Y. Li, F. Sun, T. Li

Annals of oncology, 2024-03, Vol.35 (3), p.329-330

Chi, K.N.

2024

Link zum Volltext

Verfügbarkeit prüfen

2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma

European journal of cancer (1990), 2015-09, Vol.51, p.S476-S476

2015

Link zum Volltext

Verfügbarkeit prüfen

1103 POSTER Overexpression of MiR-141 and MiR-126 Distinguishes Metastatic Castration Resistant Prostate Cancer (mCRPC) From Localized Prostate Cancer (PCa) and Controls in Human Plasma

European journal of cancer (1990), 2011, Vol.47, p.S125-S125

2011

Link zum Volltext

Verfügbarkeit prüfen

Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis

European urology open science (Online), 2020-07, Vol.19, p.e863-e864

2020

Link zum Volltext

Verfügbarkeit prüfen

4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2

European journal of cancer (1990), 2014-11, Vol.50, p.8-8

2014

Link zum Volltext

Verfügbarkeit prüfen

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2021-09, Vol.385 (12), p.1091-1103

2021

Link zum Volltext

Verfügbarkeit prüfen

The Future of Systemic Therapies for Localised Prostate Cancer

Clinical oncology (Royal College of Radiologists (Great Britain)), 2013-08, Vol.25 (8), p.506-513

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

Annals of oncology, 2013-07, Vol.24 (7), p.1802-1807

2013

Link zum Volltext

Verfügbarkeit prüfen

7056 POSTER QT/QTc Studies of Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Analysis of 3 Phase 1/2 Studies

European journal of cancer (1990), 2011, Vol.47, p.S502-S502

2011

Link zum Volltext

Verfügbarkeit prüfen

7058 POSTER Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) – a Drug-Drug Interaction (DDI) Study With Dextromethorphan HBr and Theophylline

European journal of cancer (1990), 2011, Vol.47, p.S502-S503

2011

Link zum Volltext

Verfügbarkeit prüfen

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Annals of oncology, 2016-03, Vol.27 (3), p.454-460

2016

Link zum Volltext

Verfügbarkeit prüfen

693P Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy

Annals of oncology, 2021-09, Vol.32, p.S708-S708

2021

Link zum Volltext

Verfügbarkeit prüfen

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

Annals of oncology, 2023-09, Vol.34 (9), p.772-782

2023

Link zum Volltext

Verfügbarkeit prüfen

651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study

Annals of oncology, 2020-09, Vol.31, p.S530-S531

2020

Link zum Volltext

Verfügbarkeit prüfen

648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC

Annals of oncology, 2021-09, Vol.32, p.S675-S676

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers

Annals of oncology, 2016-06, Vol.27 (6), p.1116-1122

2016

Link zum Volltext

Verfügbarkeit prüfen

258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study

Annals of oncology, 2023-11, Vol.34, p.S1573-S1574

2023

Link zum Volltext

Verfügbarkeit prüfen

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

Annals of oncology, 2014-02, Vol.25 (2), p.429-434

2014

Link zum Volltext

Verfügbarkeit prüfen

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

Annals of oncology, 2021-07, Vol.32 (7), p.896-905

2021

Link zum Volltext

Verfügbarkeit prüfen

158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study

Annals of oncology, 2022-11, Vol.33, p.S1496-S1496

2022

Link zum Volltext

Verfügbarkeit prüfen

1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH

Annals of oncology, 2022-09, Vol.33, p.S1185

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(144)

Publikationsform

Artikel
(141)
Tagungsberichte
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(40)
Humans
(30)
Oncology
(27)
Male
(25)
Aged
(15)
Middle Aged
(15)
Physical Sciences
(15)
Biological And Medical Sciences
(14)
Treatment Outcome
(14)
Medical Sciences
(12)
Technology
(12)
Aged, 80 And Over
(11)
Hematology, Oncology And Palliative Medicine
(11)
Pharmacology. Drug Treatments
(10)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(9)
Tumors
(9)
Antineoplastic Agents
(8)
Antineoplastic Agents - Therapeutic Use
(8)
Chemistry
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

262 INVITED From New Targets to New Drugs in Prostate Cancer – Other Targets

Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group

Letter to the editor regarding ‘Misclassified confounders in the second interim analysis of the MAGNITUDE trial’ by P. Chen, M. Liu, G.Y. Li, F. Sun, T. Li

2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma

1103 POSTER Overexpression of MiR-141 and MiR-126 Distinguishes Metastatic Castration Resistant Prostate Cancer (mCRPC) From Localized Prostate Cancer (PCa) and Controls in Human Plasma

Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis

4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

The Future of Systemic Therapies for Localised Prostate Cancer

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

7056 POSTER QT/QTc Studies of Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Analysis of 3 Phase 1/2 Studies

7058 POSTER Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) – a Drug-Drug Interaction (DDI) Study With Dextromethorphan HBr and Theophylline

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

693P Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study

648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC

A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers

258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study

1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH

Suchergebnisse filtern